Related Articles
MRI-Guided Neoadjuvant Chemotherapy Could be Used in HR-/HER2+ Breast Cancer
MRI-guided treatment could be used to optimize the duration of neoadjuvant chemotherapy in hormone receptor-negative/HER2-positive breast cancer.
Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.
Defining Primary Refractory Large B-cell Lymphoma
Key Points. Patients with SD/PD to 1L therapy have lower RRs to 2L therapy and poor outcomes compared to other subgroups of primary refractory diseaseWe…
Garje Elucidates Biomarker-Driven Approaches Generating Excitement in Metastatic Prostate Cancer
Rohan Garje, MD, highlights advances made in precision medicine approaches for the management of metastatic prostate cancer.
Dr Cobain on Endocrine Therapy–Based Treatment Strategies in HR+/HER2– Breast Cancer
Erin Frances Cobain, MD, discusses optimal endocrine therapy–based treatment strategies in later-line settings for HR-positive/HER2-negative breast cancer.
Data Continue to Illustrate Potential Role of Partial Breast Irradiation in Early-Stage Breast Cancer
Robert W. Mutter, MD, discusses research involving partial breast irradiation and multi-modality therapy in early-stage breast cancer.
HER2 Expression May Hold the Key to Predicting Survival Outcomes in CRC
Heinz-Josef Lenz, MD, FACP, discusses the prognostic and predictive value of HER2 expression levels in select patients with colorectal cancer.
TAR-210’s Potential to Improve Outcomes in Intermediate-Risk NMIBC
Roger Li, MD, discusses what the future may hold for the use of TAR-210 for the treatment of patients with intermediate-risk non-muscle-invasive bladder cancer with…
Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
How to reduce your breast cancer risk
Breast medical oncologist Banu Arun, M.D., discusses breast cancer risk factors and prevention.